Biology Reference
In-Depth Information
modulation of macrophage iron metabolism by tumor necrosis factor.
Lab Invest
61: 319-322
65 Rogers J, Lacroix L, Durmowitz G, Kasschau K, Andriotakis J, Bridges KR (1994) The role of
cytokines in the regulation of ferritin expression.
Adv Exp Med Biol
356: 127-132
66 Peetre C, Gullberg U, Nilsson E, Olsson I (1986) Effects of recombinant tumor necrosis factor on
proliferation and differentiation of leukemic and normal hemopoietic cells
in vitro
. Relation to cell
surface receptors.
J Clin Invest
78: 1694-1700
67 Recalcati S, Taramelli D, Conte D, Cairo G (1998) Nitric oxide-mediated induction of ferritin syn-
thesis in J774 macrophages by inflammatory cytokines: Role of selective iron regulatory protein-2
downregulation.
Blood
91: 1059-1066
68 Bertero MT, Caligaris-Cappio F (1997) Anemia of chronic disorders in systemic autoimmune dis-
eases.
Haematologia
82: 375-381
69 Domachowske JB (1997) The role of nitric oxide in the regulation of cellular iron metabolism.
Biochem Molec Med
60: 1-7
70 Weiss G, Bogdan C, Hentze MW (1997) Pathways for the regulation of macrophage iron metab-
olism by the anti-inflammatory cytokines IL-4 and IL-13.
J Immunol
158:420-425
71 Oria R, Sanchez L, Houston T, Hentze MW, Liew FY, Brock JH (1995) Effect of nitric oxide on
expression of transferrin receptor and ferritin and on cellular iron metabolism in K562 human ery-
throleukemia cells.
Blood
85: 2962-2966
72 Watts RN, Richardson DR (2000) Examination of the mechanism of action of nitrogen monoxide
on iron uptake from transferrin.
J Lab Clin Med
136: 149-156
73 Engstedt L, Johannsson S, Strandeberg O (1966) Studies in anemia and plasma protein distur-
bance.
Acta Med Scand
180: 92-106
74 Means RT, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ, O'Neil VL, Pincus T
(1989) Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin:
Clinical and
in vitro
studies.
Arthritis Rheum
32: 638-642
75 Takashima N, Kondo H, Kashwazaki S (1990) Suppressed erythropoietin response to anemia and
efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis.
J Rheumatol
17:
885-887
76 Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris R, Schnitzer T, Abels R, Boccagno J, Krantz SB
(1990) Multicenter study of recombinant human erythropoietin in correction of anemia in rheuma-
toid arthritis.
Am J Med
89: 161-168
77 Granolleras C, Branger B, Beau MC, Deschodt G, Alsabadani B, Shaldon S (1989) Experience
with daily self-administered subcutaneous erythropoietin.
Contrib Nephrol
76: 143-148
78 Gudbjornsson B, Hallgren R, Wide L, Birgegard G (1992) Response of anemia in rheumatoid
arthritis to treatment with subcutaneous recombinant human erythropoietin.
Ann Rheum Dis
51:
747-752
79 Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ (1996) Effect of recombinant human
erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia
of chronic disease: A randomised placebo controlled double blind 52 weeks clinical trial.
Ann
Rheum Dis
55: 739-744
80 Nordstrom D, Lindroth Y, Marsal L, Hafstrom I, Heinrich C, Rantapaa-Dalqvist S, Engstrom-
Laurent A, Friman C (1997) Availability of iron and degree of inflammation modifies the response
to recombinant human erythropoietin when treating anemia of chronic disease in patients with
rheumatoid arthritis.
Rheumatol Int
17: 67-73
81 Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B (2001) Effect of recombinant human
erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis.
J
Rheumatol
28: 2430-2436
82 Dohil D, Hassal E, Wadsworth LD, Israel DM (1998) Recombinant human erythropoietin for
treatment of anemia of chronic disease in children with Crohn's disease.
J Pediatr
132: 155-159
83 Corwin HL, Gettinger A, Rodriguez RM, Gubler KD, Enny C, Colton T, Corwin MJ (1999)
Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double
blind, placebo controlled trial.
Crit Care Med
2: 2346-2350
84Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S,
Schwartz D, Yachinin T et al. (2000) The use of subcutaneous erythropoietin and intravenous iron
for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and
renal function and functional cardiac class, and markedly reduces hospitalization.
J Am Coll
Cardiol
35: 1737-1744
85 Peeters HR, Jongen-Lavrencic M, Bakker CH, Vreugdenhil G, Breedveld FC, Swaak AJ (1999)
